Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial
Masafumi Oyama; Takayuki Sugiyama; Masahiro Nozawa; Kiyohide Fujimoto; Takeshi Kishida; Go Kimura; Noriaki Tokuda; Shiro Hinotsu; Kojiro Shimozuma; Hideyuki Akaza; Seiichiro Ozono
Author Information: Saitama Medical University International Medical Center, Hidaka, Japan
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.